Detail of "23214-92-8"

CAS Number:
23214-92-8
Name:
5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-,(8S,10S)-
Superlist Name:
Adriamycin
Molecular Structure:
Formula:
C₂₇H₂₉NO₁₁
Molecular Weight:
543.52
Deleted CAS:
23257-17-2|24385-08-8|25311-50-6|29042-30-6
Synonyms:
5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,(8S,10S)- (9CI);14-Hydroxydaunomycin;63: PN: WO2010011890 PAGE: 37 claimedsequence;Biotransdox;Caelyx;Doxil;Doxorubicin;Evacet;Hydroxydaunomycin;NSC 123127;PK 2;Rubex;
EINECS:
245-495-6
Density:
1.615 g/cm³
Melting Point:
205 °C
Boiling Point:
810.293 °C at 760 mmHg
Flash Point:
443.849 °C
Solubility:
soluble in water
particular:
particular

Famous Chemical Enterprises

Livzon
Total
Shell
Dupont
Exxonmobil
Akzonobel
Basf
Bayer
BP

Other Products

Supplier Location
Supplier Location
- China (Mainland)(11)
- United States(7)
- United Kingdom(2)
- Denmark(1)
- India(1)
- Italy(1)
- Switzerland(1)
Business Type
Business Type
- Lab/Research institutions(2)
- Manufacturers(0)
- Trading Company(17)
Certificates
Certificates
- ISO(1)
- Production License (0)

Please post your buying leads>>

Display：

Manufacturer
Enterprise Authentication
Suppiers of more reward points first
New supplier

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Reference

Clonogenic cell assay for carcinoma of the lung: Clonogenic cell assay for carcinoma of the lung. Kanzawa, Fumihiko; Hoshi, Akio; Shimizu, Eiji; Saijo, Nagahiro; Miyazawa, Naoto; Shimabukuro, Zentetsu (Pharmacol. Div., Natl. Cancer Cent. Res. Inst., Tokyo 104, Japan). Gann, 75(1), 81-8 (English) 1984. CODEN: GANNA2. ISSN: 0016-450X. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Studies were performed with a clonogenic cell assay system to det. the in vitro sensitivity of carcinoma of the lung to std. chemotherapeutic drugs. Formation of colonies in vitro occurred in 22 of 29 specimens (76%), including 4 of 7 squamous cell carcinomas, 11 of 16 adenocarcinomas, all of 3 large cell carcinomas, and none of 3 small cell carcinomas. Eighteen of these 22 assays (82%) showed growth which was adequate for chemosensitivity testing. 51-21-8 and 57-22-7 are cas registry numbers of chemicals which are used as reagents here. Antitumor drugs tested in this study were cis-diamminedichloroplatinum [15663-27-1], 5-fluorouracil [51-21-8], adriamycin [23214-92-8], mitomycin C [50-07-7], vindesine [53643-48-4], vincristine [57-22-7], vinblastine [865-21-4], bleomycin [11056-06-7], peplomycin [68247-85-8] and L-phenylalanine mustard [148-82-3], which are used clin. for chemotherapy for lung cancer. Of 10 drugs tested against at least 2 different tumors, vindesine and mitomycin C were identified as being active against more than 3 tumors (17%). Twelve of 18 specimens (67%) were not sensitive in vitro to any of the drugs tested. Of the remaining 6 specimens (33%) showing sensitivity to any drug, 4 tumors were sensitive to only one drug, 1 tumor was sensitive to 3 drugs and another was sensitive to 4 drugs. The in vitro chemosensitivity results seemed well correlated with clin. experience. The human tumor clonogenic cell assay system appears to be a reasonable model for the study of chemosensitivity in carcinoma of the lung. .

Preparation and characterization of doxorubicin-containing liposomes: Preparation and characterization of doxorubicin-containing liposomes. II. Loading capacity, long-term stability and doxorubicin-bilayer interaction mechanism. Crommelin, D. J. A.; Van Bloois, L. (Subfac. Pharm., Univ. Utrecht, Utrecht 3511 GH, Neth.). Int. J. Pharm., 17(2-3), 135-44 (English) 1983. CODEN: IJPHDE. ISSN: 0378-5173. DOCUMENT TYPE: Journal CA Section: 63 (Pharmaceuticals) Doxorubicin (I) [23214-92-8] loading capacity was detd. for neg. (phosphatidylcholine-cholesterol [57-88-5]-phosphatidylserine, :1) and pos. (phosphatidylcholine-cholesterol-stearylamine [124-30-1] :3) liposomes prepd. according to the film method with I added to the phospholipids before film formation. I assocn. depended on the initial ratio of I/phospholipid, the charge and the size. The max. loading capacity was 60-75 mmol I/mol phospholipid for the neg. and ~55 mmol I/mol phospholipid for pos., nonfiltered, multilamellar liposomes. Filtration or ultrasonication/ultracentrifugation reduced the I-bilayer interaction.Several substances with their cas registry numbers 57-88-5 and 23214-92-8 may be metioned in this study. Loss on storage of I from the filtered, multilamellar, or unilamellar vesicles decreased in the following order: filtered neg. < unilamellar pos. < unilamellar neg. vesicles. Pos. unilamellar vesicles increased in particle size on storage. Neg. liposomes were stable. z-Potentials of pos. or neg. liposomes did not depend on the presence of assocd. I. This makes a purely electrostatic mechanism of interaction between the drug and the bilayer unlikely. If I was added to the phospholipid film in the hydration buffer a dramatic drop in I-bilayer assocd. was obsd. for pos. liposomes. For neg. liposomes the loading efficiency was unaffected. .

Detail of "23214-92-8"

5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-,(8S,10S)-

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

CAS No.23214-92-8 Adriamycin

Reference